Efficacy of screening for gynecologic malignancies by measuring urine-blood porphyrin concentration using oral 5-aminolevulinic acid
- Conditions
- malignant genital tumors benign gynecologic tumors
- Registration Number
- JPRN-UMIN000008890
- Lead Sponsor
- agoya University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 120
Not provided
1)Patients (including tuberculosis activities) uncontrolled infection. 2)Patients with severe anamnesis (Malignant hypertension. With severe congestive heart failure. Severe liver failure. Myocardial infarction within 3 months. End-stage cirrhosis. Poorly controlled diabetes. Severe pulmonary fibrosis. Interstitial pneumonia activity) 3) Allogeneic bone marrow transplantation 4) Patients with severe mental disorders 5)Patients with porphyria or hypersensitivity to porphyrins allergy 6) A gravida, a lactational woman 7) Patients with severe anemia 8)Patients were deemed inappropriate by research investigators 9)Patients with malignant tumor during treatment. cancer patients within 5 years after treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relation between of urinary/serum porphyrins value and pathological factors in 3 groups (patients with malignant genital tumor, with benign tumor, healty person) . Receiver operating characteristic (ROC) curves are constructed for porphyrins, and the cut-off value to identify malignant tumor.
- Secondary Outcome Measures
Name Time Method